08th Sep 2022
Celix Pharma announces the launch of Abiraterone Tablets.
Celix Pharma is pleased to announce the launch of Abiraterone 500 mg film-coated tablets in the UK. Abiraterone 500mg is available in unit-dose blister packs of 56 tablets.
Abiraterone is a hormonal therapy drug, used in conjunction with steroids, for the treatment of advanced prostate cancer. Prostate cancer needs the hormone testosterone to grow. Abiraterone works by reducing the amount of testosterone made by the body, thereby controlling the growth of prostate cancer (1).
Commenting on this launch, Subir Kohli, Co-founder & CEO said, “We are excited to launch another product for our hospital pharmacy customers. Abiraterone is the first of several products within the Oncology space for Celix Pharma. With the NHS spend well over £100million on this drug (2), a high-quality, cost-effective alternative will bring in substantial savings to the NHS drugs bill.”
Shantreddy, Co-founder & COO commented, “Abiraterone is another feather in the cap for Celix Pharma, launching the product on the first day after expiry of Zytiga’s®marketing exclusivity”.
1. Source: Macmillan Cancer Support (https://www.macmillan.org.uk/)
2. IQVIA data (Dec 2021)
About Celix Pharma Ltd
Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries. Celix Pharma is building a portfolio across both, primary-care and secondary-care, with a range of generics, branded generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially-led, customer-focused organization supported with strategic partnerships in R&D and manufacturing.
For more information, visit www.celixpharma.com